$(0.23) $(0.27) $(1.11) $(0.97)
Shares used to compute
basic and diluted net
loss per share 29,801,432 29,389,130 29,670,689 29,213,098
RENOVIS, INC.
Condensed Balance Sheets
(in thousands)
December 31, December 31,
2007 2006
Assets:
Cash and cash equivalents $40,750 $41,958
Short-term investments 38,643 57,149
Prepaid and other current
assets 885 928
Total current assets 80,278 100,035
Property and equipment, net 5,236 7,052
Other long-term assets 236 214
$85,750 $107,301
Liabilities and stockholders' equity
Current liabilities $8,488 $10,531
Long-term liabilities 1,689 3,684
Stockholders' equity 75,573 93,086
$85,750 $107,301
'/>"/>SOURCE Renovis, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related biology technology :1.
Renovis to Present at CIBC World Markets Healthcare Conference2.
Renovis Reports Third Quarter 2007 Financial Results3.
Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis4.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound5.
QMed, Inc. Reports July Medicare SNP Enrollments6.
Phlo Affiliate Reports Expanded Coverage to Oregon Border7.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results8.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20079.
Carrington Reports Second Quarter 2007 Results10.
Avitar Reports Third Quarter Financial Results for Fiscal 200711.
Response Genetics Reports Second Quarter 2007 Financial Results